ECSP13012596A - Proceso de elaboración para derivados de pirimidina - Google Patents
Proceso de elaboración para derivados de pirimidinaInfo
- Publication number
- ECSP13012596A ECSP13012596A ECSP13012596A ECSP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A EC SP13012596 A ECSP13012596 A EC SP13012596A
- Authority
- EC
- Ecuador
- Prior art keywords
- solid forms
- elaboration process
- compound
- pirimidine derivatives
- pirimidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000007787 solid Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38872110P | 2010-10-01 | 2010-10-01 | |
| US201161494915P | 2011-06-09 | 2011-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012596A true ECSP13012596A (es) | 2013-07-31 |
Family
ID=44773179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012596 ECSP13012596A (es) | 2010-10-01 | 2013-04-30 | Proceso de elaboración para derivados de pirimidina |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9181215B2 (fr) |
| EP (2) | EP3040333B1 (fr) |
| JP (3) | JP5998145B2 (fr) |
| KR (2) | KR20180123586A (fr) |
| CN (3) | CN104945373A (fr) |
| AR (1) | AR083213A1 (fr) |
| AU (4) | AU2011308856B2 (fr) |
| BR (1) | BR112013007123B1 (fr) |
| CA (1) | CA2813333C (fr) |
| CL (2) | CL2013000850A1 (fr) |
| CO (1) | CO6700837A2 (fr) |
| DK (1) | DK3040333T3 (fr) |
| EC (1) | ECSP13012596A (fr) |
| ES (1) | ES2699951T3 (fr) |
| GT (1) | GT201300080A (fr) |
| HK (1) | HK1220686A1 (fr) |
| HU (1) | HUE041326T2 (fr) |
| IL (3) | IL225113A (fr) |
| LT (1) | LT3040333T (fr) |
| MX (1) | MX354482B (fr) |
| MY (1) | MY160785A (fr) |
| NZ (1) | NZ608285A (fr) |
| PE (1) | PE20140002A1 (fr) |
| PH (1) | PH12015501585A1 (fr) |
| PL (1) | PL3040333T3 (fr) |
| PT (1) | PT3040333T (fr) |
| RU (2) | RU2576619C2 (fr) |
| SG (1) | SG188439A1 (fr) |
| SI (1) | SI3040333T1 (fr) |
| TW (1) | TWI540133B (fr) |
| WO (1) | WO2012044727A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5832647B2 (ja) | 2011-07-01 | 2015-12-16 | ノバルティス アーゲー | がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法 |
| WO2013046136A1 (fr) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| AU2013336807B2 (en) * | 2012-10-23 | 2016-10-27 | Novartis Ag | Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| AP2015008707A0 (en) | 2013-03-14 | 2015-09-30 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US9318944B2 (en) | 2013-04-29 | 2016-04-19 | Rockwell Automation Technologies, Inc. | Methods and apparatus for active front end filter capacitor degradation detection |
| US9294005B2 (en) | 2013-10-01 | 2016-03-22 | Rockwell Automation Technologies, Inc. | Method and apparatus for detecting AFE filter capacitor degradation |
| NZ718487A (en) * | 2013-10-16 | 2020-01-31 | Shanghai Yingli Pharm Co Ltd | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| BR112016023811B8 (pt) | 2014-04-22 | 2023-01-10 | Piqur Therapeutics Ag | Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação |
| CN105085476B (zh) * | 2014-11-24 | 2018-03-09 | 苏州晶云药物科技有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法 |
| US10227324B2 (en) | 2014-12-17 | 2019-03-12 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof |
| US9481665B2 (en) * | 2015-03-13 | 2016-11-01 | Yong Xu | Process for preparing PI3K inhibitor buparsilib |
| CN107787226A (zh) | 2015-03-25 | 2018-03-09 | 诺华股份有限公司 | 药物组合 |
| CN105001151B (zh) * | 2015-08-28 | 2017-07-14 | 苏州明锐医药科技有限公司 | 布帕尼西中间体及其制备方法 |
| CN106543140A (zh) * | 2015-09-21 | 2017-03-29 | 苏州晶云药物科技有限公司 | 5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺盐酸盐的晶型及其制备方法 |
| ES2907574T3 (es) * | 2015-12-16 | 2022-04-25 | Genentech Inc | Proceso para la preparación de compuestos inhibidores de pi3k triciclicos y métodos para su utilización para el tratamiento del cáncer. |
| CN106905294A (zh) * | 2016-07-08 | 2017-06-30 | 苏州科睿思制药有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法 |
| CN107793394A (zh) * | 2017-08-03 | 2018-03-13 | 上海厚璞生物科技有限公司 | 一种生产选择性pi3k抑制剂的系列关键中间体 |
| CN110016142B (zh) * | 2019-04-30 | 2021-08-03 | 合肥工业大学 | 一种含嘧啶硼酸结构的硅油及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124476A (en) | 1998-04-17 | 2000-09-26 | Symyx Technologies, Inc. | Catalyst ligands, catalyst compositions, catalyst metal complexes and processes for cross-coupling aromatic boron compounds with aromatic halogens or perfluoroalkylsulfonates |
| CN1735598A (zh) * | 2002-11-11 | 2006-02-15 | 拜耳医药保健股份公司 | 作为ip受体拮抗剂的苯基或杂芳基氨基烷烃衍生物 |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP2057140B1 (fr) | 2006-08-24 | 2012-08-08 | AstraZeneca AB | Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives |
| CN101711241A (zh) * | 2007-02-06 | 2010-05-19 | 诺瓦提斯公司 | Pi3-激酶抑制剂和它们的使用方法 |
| WO2009066084A1 (fr) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3 |
| AU2010247397B2 (en) * | 2009-05-15 | 2012-07-12 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
-
2011
- 2011-09-29 US US13/825,880 patent/US9181215B2/en active Active
- 2011-09-29 SG SG2013016837A patent/SG188439A1/en unknown
- 2011-09-29 MY MYPI2013000811A patent/MY160785A/en unknown
- 2011-09-29 HU HUE16151719A patent/HUE041326T2/hu unknown
- 2011-09-29 CN CN201510157366.4A patent/CN104945373A/zh active Pending
- 2011-09-29 JP JP2013531796A patent/JP5998145B2/ja active Active
- 2011-09-29 WO PCT/US2011/053808 patent/WO2012044727A2/fr active Application Filing
- 2011-09-29 KR KR1020187032263A patent/KR20180123586A/ko not_active Application Discontinuation
- 2011-09-29 SI SI201131619T patent/SI3040333T1/sl unknown
- 2011-09-29 CN CN201510156027.4A patent/CN104987321A/zh active Pending
- 2011-09-29 EP EP16151719.8A patent/EP3040333B1/fr active Active
- 2011-09-29 NZ NZ608285A patent/NZ608285A/en not_active IP Right Cessation
- 2011-09-29 PE PE2013000654A patent/PE20140002A1/es active IP Right Grant
- 2011-09-29 RU RU2013120326/04A patent/RU2576619C2/ru active
- 2011-09-29 PL PL16151719T patent/PL3040333T3/pl unknown
- 2011-09-29 ES ES16151719T patent/ES2699951T3/es active Active
- 2011-09-29 DK DK16151719.8T patent/DK3040333T3/da active
- 2011-09-29 AR ARP110103595A patent/AR083213A1/es unknown
- 2011-09-29 KR KR1020137011172A patent/KR20130119928A/ko active Application Filing
- 2011-09-29 PT PT16151719T patent/PT3040333T/pt unknown
- 2011-09-29 AU AU2011308856A patent/AU2011308856B2/en active Active
- 2011-09-29 CN CN201180047753.2A patent/CN103140479B/zh active Active
- 2011-09-29 LT LTEP16151719.8T patent/LT3040333T/lt unknown
- 2011-09-29 RU RU2015150728A patent/RU2015150728A/ru unknown
- 2011-09-29 CA CA2813333A patent/CA2813333C/fr active Active
- 2011-09-29 EP EP11767362.4A patent/EP2621908A2/fr not_active Withdrawn
- 2011-09-29 BR BR112013007123-0A patent/BR112013007123B1/pt active IP Right Grant
- 2011-09-29 MX MX2013003507A patent/MX354482B/es active IP Right Grant
- 2011-09-30 TW TW100135673A patent/TWI540133B/zh active
-
2013
- 2013-03-07 IL IL225113A patent/IL225113A/en unknown
- 2013-03-22 CO CO13057091A patent/CO6700837A2/es unknown
- 2013-03-22 GT GT201300080A patent/GT201300080A/es unknown
- 2013-03-28 CL CL2013000850A patent/CL2013000850A1/es unknown
- 2013-04-30 EC ECSP13012596 patent/ECSP13012596A/es unknown
- 2013-09-24 HK HK16108618.7A patent/HK1220686A1/zh unknown
-
2014
- 2014-06-19 IL IL233282A patent/IL233282A/en unknown
-
2015
- 2015-02-24 AU AU2015200938A patent/AU2015200938B2/en not_active Ceased
- 2015-02-24 AU AU2015200936A patent/AU2015200936A1/en not_active Abandoned
- 2015-03-30 IL IL238046A patent/IL238046A/en not_active IP Right Cessation
- 2015-04-27 CL CL2015001088A patent/CL2015001088A1/es unknown
- 2015-05-06 US US14/705,013 patent/US9359326B2/en not_active Expired - Fee Related
- 2015-07-20 PH PH12015501585A patent/PH12015501585A1/en unknown
- 2015-10-23 AU AU2015246141A patent/AU2015246141B2/en not_active Ceased
- 2015-12-17 JP JP2015246501A patent/JP2016128414A/ja active Pending
- 2015-12-17 JP JP2015246502A patent/JP2016106091A/ja active Pending
-
2016
- 2016-05-06 US US15/147,986 patent/US9452994B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012596A (es) | Proceso de elaboración para derivados de pirimidina | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| NI201500123A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| CO6781507A2 (es) | Novedosos derivados heterociclicos | |
| CR20140399A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| CU20120099A7 (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| PE20180318A1 (es) | Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| ECSP11011206A (es) | Nuevos herbicidas. | |
| ECSP11011244A (es) | Nuevos herbicidas. | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| DOP2015000076A (es) | Benzamidas | |
| ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
| CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
| CU20110220A7 (es) | Espiro-epóxidos como productos intermedios | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. |